COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,973 Articles (22,604 medRxiv, 8,369 bioRxiv)

Most recent first Previous |  Page 1676: Articles 16751-16760  | Next

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines
Monin-Aldama, L., Laing, A. G., Munoz-Ruiz, M., McKenzie, D. R., del Molino del Barrio, I., Alaguthurai, T., Domingo Vila, C., Hayday, T. S., Graham, C., Seow, J., Abdul-Jawad, S., Kamdar, S., Harvey-Jones, E., Graham, R., Cooper, J., Khan, M., Vidler, J., Kakkassery, H., Sinha, S., Davis, R., Dupont, L., Francos Quijorna, I., Lee, P., Eum, J., Conde Poole, M., Joseph, M., Davies, D., Wu, Y., Montes, A., Harries, M., Rigg, A., Spicer, J., Malim, M. H., Fields, P., Patten, P., Di Rosa, F., Papa, S., Tree, T., Doores, K., Hayday, A. C., Irshad, S.
10.1101/2021.03.17.21253131 — Posted: 2021-03-17 Discussion: Onsite
Characteristics and risk factors for SARS-CoV-2 among children in Italy: a cross-sectional study in 20 pediatric centers
Lazzerini, M., Sforzi, I., Trapani, S., Biban, P., Salvigni, D., Mariani, I., Villa, G., Tibaldi, J., Bertacca, L., Felici, E., Perricone, G., Parrino, R., Gioe', C., Lega, S., Conte, M., Marchetti, F., Magista, A., Berlese, P., Martelossi, S., Vaienti, F., Valletta, E., Mauro, M., Dall Amico, R., Fasoli, S., Gatto, A., Chiaretti, A., Dragovic, D., Pascolo, P., Pilotto, C., Liguoro, I., Miorin, E., Saretta, F., Trobia, G., Di Stefano, A., Orlandi, A., Cardinale, F., Lubrano, R., Testa, A., Binotti, M., Moressa, V., Barbi, E., Armocida, B.
10.1101/2021.03.17.21253610 — Posted: 2021-03-17
The impact of policy timing on the spread of COVID-19
Elitzur, M., Kaplan, S., Ivezic, Z., Zilberman, D.
10.1101/2021.03.16.21253764 — Posted: 2021-03-17 Discussion: Onsite
The Influence of Covid-19 Vaccine on Daily Cases, Hospitalization, and Death Rate in Tennessee: A Case Study in the United States
Roghani, A.
10.1101/2021.03.16.21253767 — Posted: 2021-03-17
Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein
Dang, M., Song, J.
10.1101/2021.03.16.435741 — Posted: 2021-03-17
Epigallocatechin Gallate from Green Tea Effectively Blocks Infection of SARS-CoV-2 and New Variants by Inhibiting Spike Binding to ACE2 Receptor
Liu, J., Bodnar, B. H., Meng, F.-Z., Khan, A., Wang, X., Luo, G. G., Saribas, S., Wang, T., Lohani, S. C., Wang, P., Wei, Z., Luo, J., Zhou, L., Wu, J., Li, Q., Hu, W., Ho, W.
10.1101/2021.03.17.435637 — Posted: 2021-03-17
Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection
Sandberg, J. T., Varnaite, R., Christ, W., Chen, P., Muvva, J. R., Maleki, K. T., Garcia, M., Dzidic, M., Folkesson, E., Skagerberg, M., Ahlen, G., Frelin, L., Sällberg, M., The Karolinska COVID-19 Study Group, , Eriksson, L. I., Rooyackers, O., Sönnerborg, A., Buggert, M., Björkström, N. K., Aleman, S., Stralin, K., Klingström, J., Ljunggren, H.-G., Blom, K., Gredmark-Russ, S.
10.1101/2021.03.17.435581 — Posted: 2021-03-17 Discussion: Onsite
SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway
Khan, S., Shafiei, M. S., Longoria, C., Schoggins, J., Savani, R. C., Zaki, H.
10.1101/2021.03.16.435700 — Posted: 2021-03-17
SARS-CoV-2 Spike receptor-binding domain with a G485R mutation in complex with human ACE2
Weekley, C. M., Purcell, D. F. J., Parker, M. W.
10.1101/2021.03.16.434488 — Posted: 2021-03-17
Identification of ACE2 mutations that modulate SARS-CoV-2 spike binding across multiple mammalian species
Heinzelman, P., Romero, P. A.
10.1101/2021.03.16.435705 — Posted: 2021-03-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).